OXFORD EMERGENT TUBERCULOSIS CONSORTIUM LTD.
Oxford Emergent Tuberculosis Consortium Ltd. develops advanced vaccine for the prevention of tuberculosis.
OXFORD EMERGENT TUBERCULOSIS CONSORTIUM LTD.
Industry:
Biotechnology Health Care Pharmaceutical
Address:
Southampton, Southampton, United Kingdom
Country:
United Kingdom
Status:
Active
Similar Organizations
FK Laboratoriz
FK Laboratoriz is develops and markets drug for the treatment and prevention of thrombosis.
More informations about "Oxford Emergent Tuberculosis Consortium Ltd."
Emergent BioSolutions and the University of Oxford Form Joint …
OXFORD, England & ROCKVILLE, Md.--(BUSINESS WIRE)--July 23, 2008--The University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS) announced today that they have formed …See details»
Oxford-Emergent Tuberculosis Consortium Signs Commercial …
The Oxford-Emergent Tuberculosis Consortium Ltd. (OETC) is a joint venture between the University of Oxford and Emergent Product Development UK Ltd. OETC was formed with the …See details»
TB vaccine enters new clinical trials | University of Oxford
Apr 23, 2009 The Oxford-Emergent Tuberculosis Consortium Ltd, a joint venture between the University of Oxford and Emergent BioSolutions Inc, is taking the vaccine forward. ... The …See details»
Oxford University Innovation licenses tuberculosis vaccine
OXFORD, UK and ROCKVILLE, MD July 23, 2008—The University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS) announced today that they have formed a joint venture, The …See details»
Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine ...
The Oxford-Emergent Tuberculosis Consortium Ltd ("OETC") is a joint venture between the University of Oxford and Emergent BioSolutions . OETC was formed with the aim of …See details»
New Tuberculosis Vaccine Enters Phase IIb Proof-of-Concept Trial …
Aug 11, 2011 The Oxford-Emergent Tuberculosis Consortium Ltd ("OETC")is a joint venture between the University of Oxford and Emergent BioSolutions. OETC was formed with the aim …See details»
Oxford Emergent Tuberculosis Consortium Ltd. - Crunchbase
Oxford Emergent Tuberculosis Consortium Ltd. is located in Southampton, Southampton, United Kingdom. Who are Oxford Emergent Tuberculosis Consortium Ltd. 's competitors? …See details»
OXFORD-EMERGENT TUBERCULOSIS CONSORTIUM LIMITED
More for OXFORD-EMERGENT TUBERCULOSIS CONSORTIUM LIMITED (06631227) Registered office address Latimer House, 5 Cumberland Place, Southampton, Hampshire, …See details»
TB Vaccine Enters New Clinical Trials - ScienceDaily
May 1, 2009 The Oxford-Emergent Tuberculosis Consortium Ltd is a joint venture between the University of Oxford and Emergent Product Development UK Ltd. The Consortium was formed …See details»
The Oxford-Emergent Tuberculosis Consortium Ltd. - Drug …
Sep 14, 2024 Explore The Oxford-Emergent Tuberculosis Consortium Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Drug:MVA-85A. Biomedical products DataSee details»
TB vaccine tested in people with HIV | University of Oxford
Aug 11, 2011 The vaccine was licensed in July 2008 to a new partnership between Oxford University and the biotech company Emergent BioSolutions, called the Oxford-Emergent …See details»
Emergent BioSolutions and Oxford University form TB Vaccine jv
Jul 24, 2008 The University of Oxford, through its technology transfer office, Isis Innovation Ltd, has exclusively licensed the MVA85A tuberculosis vaccine candidate and related technology …See details»
Milestone in clinical trial of improved TB vaccine developed in …
The trial is being conducted by the University of Cape Town’s South African Tuberculosis Vaccine Initiative (SATVI), in partnership with Aeras, the Wellcome Trust, and the Oxford-Emergent …See details»
Oxford-Emergent Tuberculosis Consortium - VentureRadar
OETC Ltd is a joint venture between the University of Oxford and Emergent BioSolutions Inc, formed to develop the world’s most clinically advanced new tuberculosis vaccine – MVA85A. …See details»
Oxford-Emergent Tuberculosis Consortium Signs Commercial …
The Oxford-Emergent Tuberculosis Consortium Ltd . (OETC) is a joint venture between the University of Oxford and Emergent Product Development UK Ltd. OETC was formed with the …See details»
Emergent BioSolutions and the University of Oxford Form Joint …
Tuberculosis Vaccine Initiative (SATVI) in Worcester, South Africa. The Consortium has secured GBP 8 million (approximately $16 million) from The Wellcome Trust and the Aeras Global TB …See details»
MVA-85A - Drug Targets, Indications, Patents - Synapse - Patsnap
Originator Organization. University of Oxford. ... The Oxford-Emergent Tuberculosis Consortium Ltd. University of Oxford. Drug Highest Phase Discontinued Phase 2. First Approval Date …See details»
Emergent BioSolutions Observes World TB Day
The World Health Organization estimates that there are over 9 million new TB cases and 1.7 million deaths from TB annually. ... "As a collaborator in the Oxford-Emergent Tuberculosis …See details»
Oxford and Emergent Biosolutions form TB vaccine consortium
Jul 22, 2008 Consortium formedThe University of Oxford and Emergent BioSolutions Inc. have announced a joint venture, The Oxford–Emergent Tuberculosis Consortium Ltd, to develop …See details»
New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial …
Vaccine Foundation, the Oxford-Emergent Tuberculosis Consortium Ltd. ("the Consortium"), Isis Innovation Ltd., the Wellcome Trust and the University of Cape Town (UCT) announce today …See details»